Diagnosis and Management of Rare Immune-Related Adverse Events

  • Schoenfeld S
  • Aronow M
  • Leaf R
  • et al.
25Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Oncologic treatment is being revolutionized by a burgeoning number of immune checkpoint inhibitors (ICPis). To date, seven ICPis have received Food and Drug Administration approval, targeting cytotoxic T‐lymphocyte antigen, programmed cell death, or programmed cell death ligand. Adverse events associated with checkpoint inhibition have been described in the literature. Guidelines exist for the most common of these, but as the use of ICPis becomes more common, the number of patients presenting with rare events will increase. This article reviews the diagnosis and management of rare ocular, hematological, luminal gastrointestinal, and rheumatological toxicities arising from ICPi treatment. Key Points As the use of immune checkpoint inhibitors (ICPis) becomes more common, the number of rare immune‐related adverse events (irAEs) will increase. A high level of suspicion is required to identify and treat these toxicities. Although it can be difficult to definitively attribute rare irAEs to ICPis, a temporal and mechanistic relationship and the absence of other etiologies should make the treating physician suspicious for a rare irAE. Certain rare irAEs, such as celiac disease, do not require treatment with glucocorticoids. Thus, differentiating this irAE from other gastrointestinal irAEs has important implications for treatment.

References Powered by Scopus

Improved survival with ipilimumab in patients with metastatic melanoma

12782Citations
N/AReaders
Get full text

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

8121Citations
N/AReaders
Get full text

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

8085Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance

116Citations
N/AReaders
Get full text

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

86Citations
N/AReaders
Get full text

Immune checkpoint inhibitor-associated celiac disease

48Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schoenfeld, S. R., Aronow, M. E., Leaf, R. K., Dougan, M., & Reynolds, K. L. (2020). Diagnosis and Management of Rare Immune-Related Adverse Events. The Oncologist, 25(1), 6–14. https://doi.org/10.1634/theoncologist.2019-0083

Readers over time

‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

57%

Researcher 5

24%

Lecturer / Post doc 3

14%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

69%

Agricultural and Biological Sciences 4

13%

Nursing and Health Professions 3

9%

Biochemistry, Genetics and Molecular Bi... 3

9%

Save time finding and organizing research with Mendeley

Sign up for free
0